Shoulder pain patients in primary care - Part 1:Clinical outcomes over 12 months following standardized diagnostic workup, corticosteroid injections, and community-based care by Laslett, Mark et al.
Bond University
Research Repository
Shoulder pain patients in primary care - Part 1
Laslett, Mark; Steele, Michael; Hing, Wayne A; McNair, Peter; Cadogan, Angela
Published in:
Journal of Rehabilitation Medicine
DOI:
10.2340/16501977-1860
Published: 01/01/2014
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Laslett, M., Steele, M., Hing, W., McNair, P., & Cadogan, A. (2014). Shoulder pain patients in primary care - Part
1: Clinical outcomes over 12 months following standardized diagnostic workup, corticosteroid injections, and
community-based care. Journal of Rehabilitation Medicine, 46(9), 898-907. https://doi.org/10.2340/16501977-
1860
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 10 May 2019
J Rehabil Med 46
ORIGINAL REPORT
J Rehabil Med  2014; 46: 898–907
© 2014 The Authors. doi: 10.2340/16501977-1860
Journal Compilation © 2014 Foundation of Rehabilitation Information. ISSN 1650-1977
Objective: Measure changes in pain and disability of prima-
ry care shoulder pain patients over a 12-month period.
Design: A non-randomized audit with repeated measures of 
pain and disability at 3 weeks, 3, 6 and 12 months.
Patients: Of 208 patients, 161 agreed to participate with 
96.9%, 98.1%, 86.3%, 83.9% follow-up at 3 weeks, at 3, 6 
and 12 months, respectively. Mean age was 44 years, mean 
symptom duration 3.6 months.
Methods: Patients were treated with protocol driven corti-
costeroid injection and community based care. Primary out-
come measure was the Shoulder Pain and Disability index 
(SPADI) questionnaire. Based on the SPADI and minimal 
clinically important difference (MCID), outcomes were cat-
egorized into: total recovery, 90% or more improved, better, 
unchanged and worse.
Results: There was significant reduction of pain and disabil-
ity at 3 weeks (p < 0.001), no change at the 3- and 6-month 
follow-up and a significant reduction at the 12-month follow-
up (p < 0.001). Excellent outcomes were achieved by 32.9% 
and 45.3%, and a poor clinical outcome resulted for 32.8% 
and 14.9% at the 3- and 12-month follow-up, respectively.
Conclusion: Though there was significant improvement at 
the 3-week and 12-month follow-up, 45% achieved an excel-
lent outcome and a 16.7% of patients were the same or worse 
than baseline at 12 months.
Key words: shoulder pain; diagnosis; follow-up studies; primary 
health care; corticosteroid injection.
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IntRoductIon
Shoulder pain is a common and disabling complaint. the 
reported annual incidence of shoulder pain in primary care is 
14.7 per 1,000 patients per year (1) with a lifetime prevalence 
of up to 70% (2). Recovery from shoulder pain can be slow and 
recurrence rates are high with 25% of those affected by shoul-
der pain reporting previous episodes, and 40 to 50% reporting 
persisting pain or recurrence at 12 months follow-up (3–5). 
Guidelines for physiotherapy interventions exist (6) and there 
are broader recommendations and protocols available (7–19), but 
most general reviews are over 10 years old or refer to specific 
conditions or methods of treatment. With the exception of two 
guidelines (7, 18), recommendations are based on practice mod-
els in Europe and north America and are focused on management 
by general medical practitioners and surgical specialists. In new 
Zealand and Australia, initial contact with the health system for 
patients with musculoskeletal pain is usually a general medical 
practitioner (GP) or a physiotherapist in the private practice or 
acting as a triage clinician in a public hospital environment. 
there is limited evidence regarding the optimal diagnostic and 
therapeutic management protocol and no available data on the 
efficacy of the approach or outcomes associated with application 
of guideline informed principles (18, 17). the nature of care in 
the first 3 months after contact is likely quite heterogeneous and 
information about outcomes is lacking. 
While outcomes of management of shoulder pain have been 
studied (5, 19–27), the heterogeneity of management protocols 
in these studies and in new Zealand primary care confound an 
understanding of reasonable expectations for recovery, need 
for imaging, the value of injection therapies, and surgery in the 
new Zealand environments. there is a need for basic data on 
outcomes associated with guideline informed community based 
care of shoulder pain presenting to primary care generally and 
in Australasia. the aim of this study was to document outcomes 
in shoulder pain patients over a 12-month period following a 
comprehensive and standardized diagnostic work up, manage-
ment with community based care and a standardized protocol 
for steroid injection. Part 2 of this report presents predictive 
modelling for outcomes at 3- and 12-month follow-up.
MEthodS
consecutive patients presenting to their GP or physiotherapist for the 
first time with a new episode of shoulder pain were invited to participate 
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in a diagnostic study during which they received a series of baseline di-
agnostic tests that included a standardised clinical examination, shoulder 
x-ray series, diagnostic ultrasound scan and diagnostic injections of local 
anaesthetic into the subacromial bursa (SAb) and acromioclavicular 
joint (AcJ). those not reporting a positive anaesthetic response (PAR) 
(≥ 80% reduction of pain about 15 min post procedure) to the SAB and 
AcJ diagnostic injections, also received an intra-articular glenohumeral 
joint (GhJ) injection as part of a MR arthrogram procedure. these pro-
cedures are described in detail elsewhere (28–31). following completion 
of the diagnostic tests, all participants were invited to participate in a 
12-month follow-up study. Study approval was acquired from The New 
Zealand Ministry of health Regional Ethics committee and informed 
consent was acquired at an initial appointment prior to commencement 
of the follow-up study. those patients reporting a PAR in post-injection 
pain intensity following one of the diagnostic injections were offered 
a therapeutic corticosteroid injection (cSI) to be delivered to the 
structure(s) identified by anaesthetic response using either ultrasound 
or fluoroscopic guidance. 
Patients were followed up at 3 weeks, 3, 6 and 12 months. All follow-
up assessments were carried out by the lead author (Ml) except for two 
that were carried out by a co-author (Ac). for patients receiving guided 
CSI procedures, the first follow-up assessment occurred approximately 
three weeks after the CSI procedure during which time firm instruc-
tions to engage in “relative rest”, i.e. no vigorous shoulder activity or 
high loads, was emphasized. At the 3 week follow-up, patients were 
referred back to the referring clinician for on-going management. All 
management after the 3 week follow-up was uncontrolled and followed 
usual community based conservative care in the form of physiotherapy 
(exercise, soft tissue and joint mobilisation, guidance on return to 
usual work and physical activities), corticosteroid injection or no 
treatment at all. documentation of received treatments were based 
on patient self-reports only. no formal advice was given to patients 
by the researchers after the 3-week follow-up.
Outcome measures
Measures used at baseline, 3 weeks, 3, 6 and 12 months follow-up: 
1. Shoulder Pain and Disability Index (SPADI) questionnaire (32, 
33). This questionnaire has 5 pain- and 8 function-related questions 
scored from 0 to 10 where 0 = no pain or disability and 10 = maxi-
mum pain or disability. these scores generate pain and disability 
subscales and a total score, which were all percentalized.
2. three 100-mm visual analogue scales (vAS) for pain intensity (pain 
at lowest, mean and worst in last 48 h) (34).
3. Fear Avoidance Beliefs Questionnaire (FABQ). This questionnaire 
generates “general”, “physical activity” and “work” subscales and 
a total score is also calculated (35). 
4. Short Form 8 item general health questionnaire (SF-8) with two 
subscales: Physical component Score (PcS) and Mental component 
Score (MCS) used to reflect two distinct dimensions of general health 
(36).
5. Global disability rating scale (33). this likert scale has 7 options: 
“no disability”, “Almost no disability”, “Minimal disability”, “Some 
disability”, “Moderate disability”, “A lot of disability”, and “Maxi-
mum disability” which were coded 1–7, respectively.
Data analysis
Baseline and all follow-up assessment data were acquired on stand-
ardized forms and data transferred to a SPSS version 20 database. 
All analyses were carried out using SPSS statistical software with 
the alpha level set to p < 0.05. to determine which baseline variables 
were significantly associated with SPADI results, correlations were 
calculated for continuous baseline variables and independent sample 
t-tests or 1-way AnovAs were calculated for discrete baseline vari-
ables. A repeated measures AnovA was used to determine if the SPAdI 
scores changed significantly over the 5 time periods.
the minimally clinically important difference (McId) for the 
primary outcome measure, the SPAdI total (%) score, was set at ± 
13 percentage points (37). typically, patients seek complete recovery 
from pain and a return to normal activities, but this has been reported 
to be achieved in only 50% by 6 months (21). In this study we created 
categories enabling identification of those achieving clinically relevant 
outcomes. the McId was used to identify those cases achieving 
less than highly satisfactory outcomes. the categories were based 
on changes in SPAdI total percentage scores between assessments: 
1. Excellent outcome: Score reduced to zero between assessment points 
or improvement was 90% or more from baseline; 
2. better: Percentage reduction in score larger than the McId but less 
than 90%;
3. Poor outcome: change (increase or decrease) in score was less than 
the McId or increase in score was more than the McId. 
All appropriate variables were considered for possible inclusion 
into predictive models of 12 month outcome, and were identified in 
two ways:
1. those variables associated with SPAdI total score at 3 and 12 
months (p ≤
  0.2).
2. All other variables in our dataset that measured a similar conceptual 
construct as variables identified in previous research (5, 21) as pre-
dictive of outcome at any time point were included. See Appendix I 
for full list of initial selection of variables.
All potential predictor variables were evaluated separately in uni-
variate logistic regressions with the dependent variables being the 
three different clinical outcomes: excellent; better; poor. Statistical 
significance was set where p < 0.05.
RESultS
two hundred and eight participants were enrolled in the 
diagnostic study and received baseline diagnostic tests. one 
hundred and sixty-one subjects (77.4%) agreed to participate 
in the follow-up study with 156 (96.9%) followed up at 3 
weeks, 158 (98.1%) at 3 months, 139 (86.3%) at 6 months and 
135 (83.9%) at 12 months (Fig. 1). There was no significant 
gender difference between those declining participation and 
those enrolling in the follow-up study (Pearson Chi-square 
p = 0.2). one way AnovA of mean values for baseline age, 
SPAdI subscale and total scores, Sf-8 mental and physical 
component scores, mean and worst pain vAS scores, fAbQ 
Work general and total scores were not significantly different 
between participants and non-participants (p > 0.1). Mean 
fAbQ Physical Activity subscale and the vAS score for lowest 
pain intensity in the preceding 48 h were lower (p = 0.005 and 
0.02, respectively) for those declining participation. table I 
presents basic demographic profiles for included patients. Table 
II presents mean values for key outcome measures taken at 
baseline, 3 weeks, 3, 6 and 12 months. during the 12-month 
follow-up period, some patients were not followed up for a 
variety of reasons. three patients withdrew because of time 
constraints, one patient withdrew because the researchers 
were not ‘doing anything’. the remainder of the cases where 
data are missing reflect patients failing to show for scheduled 
appointments and being unable to be contacted. In these cases 
multiple attempts over several weeks were made to contact 
patients and often contact was re-established. 
of the 161 patients enrolled, 37%, 15% and 9% reported 
a PAR to diagnostic injection to the SAb, AcJ and GhJ, re-
spectively. There was no significant gender difference between 
those reporting a PAR or negative anaesthetic response (nAR) 
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(Pearson chi-square p > 0.3). one way AnovA analyses of 
SPAdI total and subscales, pain intensity vAS scores, Sf-8 
PcS and McS, Global disability rating, and fAbQ total and 
subscales for those reporting PAR from at least one structure 
injection, showed no significant differences from those report-
ing a negative anaesthetic response (nAR) (p > 0.1).
the majority of patients were managed with physiotherapy 
interventions (mostly exercise, mobilization and guidance on 
activity modification), and corticosteroid injection. Corticos-
teroid injection (cSI) was arranged at the initial interview by 
the principal author (Ml) in accordance with reported PAR, 
i.e. ≥ 80% pain reduction criterion used to identify the source 
of pain (28). Fifty-five, 18 and 16 patients received guided 
cSI to the SAb, AcJ and GhJ, respectively. of the 13 pa-
tients with both SAb and AcJ sources of pain, one received 
guided cSI to both structures, 4 and 6 received cSI to the 
AcJ and SAb respectively based on the clinical judgement 
of the lead author or Sports Medicine specialist, and two 
declined further injections. one patient received guided cSI 
into a paralabral synovial cyst and another, an injection into 
Fig. 1. Diagram of flow of patients through diagnostic and follow-up studies. LA: guided local anaesthetic injection; CSI: corticosteroid injection; 
PAR: positive anaesthetic response, i.e. ≥ 80% relief of pain. Source participants derived from Cadogan 2011 (28).
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the sternoclavicular joint. After the 3 weeks follow-up, two 
patients were managed by rheumatology specialists. other 
interventions used were: hydraulic distension combined with 
cSI to the glenohumeral joint (n = 4), aspiration followed 
by cSI to synovial cysts associated with labral pathology 
(n = 2), fenestration and barbotage to calcific tendinopathies 
in conjunction with cSI to the subacromial bursa (n = 2), and 
one patient received prolotherapy. by the 12-month follow-up 
assessment, 29 patients had been offered and 19 had undergone 
surgical intervention. At the 12-month assessment 5 were 
scheduled to have surgery. Insurance coverage for surgery was 
declined in 3 cases so it did not proceed, and one patient chose 
not to proceed because of clinical improvement. to determine 
if there were significant baseline differences between those 
patients offered or had received surgery compared with those 
not considered surgical candidates, one way AnovA analy-
ses were carried out on relevant measures (SPAdI total % 
and Pain and disability sub-scales, pain intensity vAS scores, 
table I. Demographic profile of patients included in shoulder pain follow-up study
 n (%) Missing, n Min–Max Mean (Sd)
Age, years 161 0 18–81 44.00 (13.88)
duration of symptoms, days 158 3 2–1,697 108.35 (193.88)
SPAdI Pain subscale, % 161 0 0–100 50.56 (21.72)
SPAdI disability subscale, % 161 0 0–93 30.25 (21.10)
SPAdI total, % 161 0 0–94 38.03 (20.11)
Pain intensity in last 48 h, 100 mmvAS
lowest 157 4 0–66 7.30 (14.33)
Mean 157 4 0–84 36.35 (20.65)
Worst 159 2 0–100 62.42 (23.50)
Global disability Rating Score (1–7) 161  1–6 3.64 (1.45)
fAbQ General Score, % 155 6 0–74 25.11 (22.68)
fAbQ Physical Activity Score, % 158 3 0–100 61.89 (23.37)
fAbQ total (Work + Physical Activity Subscales), % 158 3 0–78 27.01 (16.69)
fAbQ Work Score, %) 156 5 0–82 38.48 (18.60)
Sf-8 Mental component Score 160 1 0–61 44.02 (8.64)
Sf-8 Physical component Score 160 1 0–66 52.38 (9.07)
Male gender 79 (49.1) 0
Right side affected 88 (54.7) 0
dominant right hand 142 (88.2) 0
diabetes – (0.0) 0
heart disease 3 (1.9) 3
Asthma 29 (18.0) 4
Smoker 31 (19.3) 4
Pain at night 87 (54.0) 7
unable to sleep on painful side 87 (54.0) 10
occupational demand on shoulder – (13.0) 21
low 52 (32.3)  
Moderate 50 (31.1)  
high 38 (23.6)  
Sport/recreational demand on shoulder – (13.7) 22
low 28 (17.4)  
Moderate 37 (23.0)  
high 74 (46.0)  
description of current episode – (0.7) 1
Recurrent episode 132 (82.0)  
new episode 28 (17.4)  
Mechanism/cause of pain onset – (1.2) 2
trauma 57 (35.4)  
Strain 70 (43.5)  
Repetitive/overuse 16 (9.9)  
unknown/spontaneous 16 (9.9)  
Employment – (2.5) 4
In paid employment 128 (79.5)  
Retired 13 (8.1)  
home with children/maternity leave 2 (1.2)  
Unable to work/sickness benefit 1 (0.6)  
unemployed 4 (2.5)  
Student 8 (5.0)  
other 1 (0.6)  
Min: Minimum; Max: Maximum; Sd: standard deviation; SPAdI: Shoulder Pain and disability Index; vAS: visual analogue scale; fAbQ: fear 
Avoidance beliefs Questionnaire; Sf-8: Short form 8.
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Global disability Rating, fAbQ total and subscales, Sf-8 
Mental and Physical component scores, and age). only base-
line fAbQ Physical Activity subscale and total scores were 
significantly higher for the surgical group (p > 0.02 and 0.03, 
respectively). however, with the exception of Sf-8 mental 
component and physical component scores at 3 weeks, the 
physical component scores at 3 months and both component 
scores at 6 months, all scales of the SPADI questionnaire were 
significantly higher for the surgical group at 3 week, 3 month 
and 6 month follow-up (p < 0.05).
Physiotherapy treatment
of the 152 patients where data are available, 76.6% received 
physiotherapy (mean number of treatments 6.9, (standard de-
viation (Sd) 8.91)). during the 12-month study period, 39.5% 
received between one and 5 treatments, and 29.6% received 
15 or more treatments. the maximum number of treatments 
was 55, with 3 surgical patients (2.6%) receiving more than 
40 pre and post-operative treatments combined. the percent-
age subsidized by the universal Accident compensation and 
Rehabilitation insurance scheme (Acc) was 90.1%. 
Therapeutic outcomes
At baseline SPAdI pain and disability sub-scales showed sig-
nificant gender differences with females reporting higher scores 
(one way AnovA, p = 0.009 and p < 0.001 respectively). 
These differences were not retained at subsequent follow-up 
assessments (p > 0.05). Repeated measures AnovA analysis 
with 5 levels of SPAdI scores (baseline, 3 weeks, 3 months, 
6 months and 12 months) with gender and duration of symp-
toms as factors, and baseline pain intensity vAS (average), 
Sf-8 PcS and McS, fAbQ (total%), GdR and age (years) as 
covariates, revealed a consistent pattern of change over time. 
for this reason, only the SPAdI total percentage score values 
are reported here. There was a significant reduction in SPADI 
total scores expressed as mean percentage values between the 
baseline assessment and all follow-up assessments (p < 0.001). 
fig. 2 shows the pattern of change over 12 months for both 
genders, SPAdI total percentage scores, and for the SPAdI 
subscales of pain and disability. the change in SPAdI scores 
was significant between baseline and the 3-week assessment 
(p < 0.001), and between the 6- and 12-month assessments 
(p < 0.001), but non-significant between the 3-week and 
6-month assessments (p > 0.1). 
fig. 3 presents data for proportions of change categories at 
3 weeks, 3, 6 and 12 months. thus at 12 months, 16.1% were 
lost to follow-up leaving a total sample size of 135. using an 
intention-to-treat approach, 45.3% achieved an excellent clinical 
result, about 28.6% were improved more than the McId but less 
than 90% better, 13.0% were not clinically different and 1.9% 
had worsened. the status of patients was generally poorest at the 
3 month follow-up, with 63.3% of patients improved beyond the 
McId and 34.8% either unchanged or worse (fig. 4). 
A large number of variables were assessed by univariate 
logistic regression analyses for a relationship with 3 clinical 
outcomes (excellent, better, poor) at 3- and 12-month follow-up, 
and the results for key variables are presented in the appendix. 
table II. Outcome measure scores from baseline to 12 month follow-up
baseline
Mean (Sd)
3 week fu
Mean (Sd)
3 Month fu
Mean (Sd)
6 month fu
Mean (Sd)
12 month fu
Mean (Sd)
SPAdI Pain % 50.6 (21.72) 21.9 (23.13) 24.6 (25.42) 24.2 (25.28) 15.0 (21.34)
SPAdI disability % 30.2 (21.10) 12.3 (17.89) 12.8 (19.12) 12.6 (18.13) 7.0 (14.47)
SPAdI total % 38.0 (20.11) 16.1 (19.22) 17.5 (20.96) 17.0 (20.16) 10.1 (16.43)
100 mm Pain vAS
lowest 7.3 (14.33) 4.7 (12.12) 4.8 (11.46) 3.6 (10.51) 1.8 (7.26)
Mean 36.4 (20.65) 13.2 (20.02) 14.7 (20.41) 15.0 (21.56) 8.4 (17.65)
Worst 62.4 (23.50) 25.3 (29.85) 27.9 (30.48) 29.2 (32.27) 17.3 (28.13)
Global disability Rating (1–7) 3.6 (1.45) 2.4 (1.52) 2.3 (1.57) 2.4 (1.68) 1.7 (1.23)
visual analouge scale (vAS) scores are the subjects rating from 0 to 100 in previous 48 h, where 0 = no pain and 100 = worst imaginable pain.
fu: follow-up; Sd: standard deviation.
Fig. 2. change in mean Shoulder Pain and disability Index (SPAdI) 
subscales and total percentage scores from baseline to 12 month follow-
up (fu) assessments. covariates appearing in the model are evaluated at 
the following values: Global disability Rating at baseline = 3.68, fAbQ 
(fear-Avoidance beliefs Questionnaire) total (%) (Work + Physical 
Activity Subscales) at baseline = 37.84, Short form 8 (Sf-8) Physical 
component Score at baseline = 43.68, Sf-8_Mental component Score 
at baseline = 53.42, Sc: average vAS Score (0-100) in last 48 h (mm) at 
baseline = 36.58.
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Excellent outcomes at 3 months were associated with: higher 
total SPAdI scores at baseline, lower maximum reported pain 
vAS scores in the 48 h prior to enrolment in the study, lower 
pain scores with painful index tests carried out at the 3-week 
follow-up assessment, a PAR following diagnostic injection of 
local anaesthetic into the GhJ and the presence of subacromial 
bursa pathology(ultrasound imaging of thickening, fluid or 
calcification). Excellent outcomes at 12 months were associ-
ated with: Report of pain not being eased or ‘best’ when at 
rest, lower reported pain scores with painful index tests carried 
out at the 3-week follow-up assessment and a PAR following 
block of the AcJ. only a PAR to diagnostic block to the SAb 
was associated with being classified as “Better” (improved 
beyond the McId but less than 90% better) at 3-month follow 
up (p = 0.009). being “better” at 12-months follow-up was as-
sociated with: A report of pain being eased at best when at rest, 
higher reported pain scores with painful index tests carried out 
at the three week follow up assessment, and a PAR to diagnostic 
block to the AcJ. A poor outcome at 3-month follow-up was 
associated with: higher fAbQ Work subscale 
scores at baseline and higher reported pain scores 
with painful index tests carried out at the three 
week follow up assessment. A poor outcome at 
12-month follow-up was associated with a lower 
Sf-8 General health subscale score at baseline 
and a PAR to diagnostic block of the AcJ.
Recurrences and re-injury rates
At each follow-up subjects were asked to recall 
and report recurrences of pain and re-injuries that 
may have occurred (table III), with nearly half of 
all pain recurrences related to re-injury. Re-injury 
was defined as a significant traumatic event or 
a significant repetitive overload situation that 
the patient clearly connected to a rapid return or 
increase in the typical shoulder pain.
dIScuSSIon
This study provides the first detailed report of outcomes for 
patients receiving community based primary care interventions 
for shoulder pain in a new Zealand environment. Manage-
ment of patients throughout the follow-up period was broadly 
consistent with recommended guidelines (7, 17, 18) and with 
treatments recommended in a recent systematic review of stud-
ies of impingement syndrome (38–40), but were not directed. 
the outcomes at 12 months are broadly consistent with those 
established in previous reports (1, 3, 7). Also consistent with 
previous reports, recurrences were reported by 13.5% by 
the 3-month follow-up and 24% by the 12-month follow-up. 
however, in the current study about half of these recurrences 
were related to re-injury, so the spontaneous recurrence rate 
at 12 months was 14% in this study. 
Corticosteroid anti-inflammatory injection is re-
ported to be effective for short term relief of shoulder 
pain (41). In the current study, the majority of patients 
receiving corticosteroid injection were selected for this 
procedure based on a highly standardized criterion, i.e. 
≥ 80% reduction of pain following a guided diagnostic 
injection into the subacromial bursa, acromioclavicular 
joint or glenohumeral joint. though diagnostic block 
has been incorporated into the diagnostic work up in 
one previous study (42), to our knowledge, this is the 
first report of outcomes where such a stringent criterion 
for cSI has been used for the great majority of patients 
which were carried out within the first 3 weeks of the 
study. no other interventions had commenced until 
after the 3-week assessment. 
Previous reports established a significant relationship 
between a shorter duration of symptoms at presentation 
and better outcome at 6 weeks and 6 months (43). this 
relationship was not supported by our data as there was 
no association between duration of symptoms prior to 
baseline assessment and the likelihood of an excellent 
Fig. 3. Proportions of change categories in shoulder pain patients at follow-up 
assessments. SPAdI: Shoulder Pain and disability Index. 
Excellent 
clinical 
outcome 
Improved 
"Better" 
Poor clinical 
outcome Missing data 
% @ 3 weeks 31,1 32,9 32,9 3,1 
% @ 3 months 32,9 30,4 34,8 1,9 
% @ 6 months 31,7 28,6 26,1 13,7 
% @ 12 months 45,3 23,6 14,9 16,1 
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Fig. 4. clinical outcomes based on Shoulder Pain and disability Index (SPAdI) 
total % at follow-up assessments. Excellent clinical outcome: SPAdI total % 
reduced by 90% or more. Improved: SPAdI total % reduced more than McId 
but less than 90% improvement. Poor clinical outcome: SPAdI total % not 
reduced by McId (13 points) or worse.
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outcome at 3 weeks or 3 months. These findings suggest that 
the structured timing of steroid injection carried out on 54% 
of the 156 patients assessed at 3 weeks was a factor in the 
observed rapid change, and may also account for the differ-
ences with previous reports (3, 43). It is noted that reports in 
2009 and 2012 suggest that the added specificity provided by 
image guidance does not provide additional benefit in terms of 
accuracy of injectate placement or clinical outcome (44, 45). 
However, in 2008 we chose to use ultrasound or fluoroscopic 
guidance for diagnostic and therapeutic injections to assist in 
validation of injectate placement. 
The profile of treatment in the current study differed sub-
stantially from the study by kuijpers et al. (43) in that over 
50% versus 12%, respectively, received corticosteroid injection 
and 77% versus 10%, respectively, received physiotherapy 
treatment. In addition, the great majority of cSI interventions 
occurred in the first 3 weeks. It seems reasonable to argue that 
the improvement observed in the first 3 weeks was related 
to corticosteroid injection independently of the duration of 
symptoms. the reason for the plateau in improvement between 
3-week and 3-month follow-ups, and the subsequent significant 
improvement between the 6-month and 12-month follow-ups 
cannot be determined based on our data. Examination of these 
observations was beyond the design and scope of this study 
and should receive attention in future research. A proportion of 
patients received steroid injection after the 3 week assessment: 
15 between the 3-week and 3-month assessments, 8 between 
3-month and 6-month follow-ups and 9 patients between 6- and 
12-month follow-up. the contribution of these interventions 
on the average clinical course could not be distinguished from 
improvement over time and the community-based interven-
tions (mostly physiotherapy) employed in the majority of 
cases. Medication use during this period was not accurately 
assessed and it is also possible that during this period the use 
of oral medications may have had an effect on overall decline 
in pain and disability. 
Patients who were offered or had received surgery for their 
shoulder problem were not significantly more painful or disabled 
at baseline, but did have elevated fear avoidance with regard 
to physical activity. However, significant differences emerged 
throughout the first 6 months of follow-up suggesting that fail-
ure to improve with conservative care or steroid injection were 
important factors in selection for surgical intervention.
Mean pain and disability generally (but not significantly) 
increased or stayed about the same between the 3-week and 
6-month assessments and then significantly declined between 
the 6- and 12-month follow-up. This finding is contrasted to 
previous reports and opinion that suggest that reductions in 
pain and disability are not expected after 6 months (3, 22, 
43). The reason for the difference in findings is unclear. It is 
important to acknowledge that during this period, some patients 
improved, some remained unchanged and others worsened. 
Some patients received surgical interventions (n = 17), which 
typically caused a major increase in pain for a variable amount 
of time in the post-surgery period. 
The predictive value of findings from imaging studies such 
as x-ray, ultrasound and magnetic resonance imageing (MRI) 
was limited. Though the presence of SAB thickening, fluid or 
calcification is associated with an excellent outcome or being 
“better” at 3 months, it must also be remembered that those 
patients being offered guided corticosteroid injections into the 
bursa were those that had a positive response to guided diag-
nostic block to the SAb. curiously, a PAR block to the SAb 
was not predictive of a good outcome. It is intended to examine 
this apparent paradox in future analyses. Another paradox that 
emerged needs further detailed examination: A positive response 
to anaesthetic block into the AcJ was associated with an excel-
lent clinical outcome at 12 months, and a poor outcome at 12 
months, suggesting that there are at least two different types of 
painful ACJ pathologies. The presence of ultrasound verified 
large or medium sized rotator cuff tear, MRI verified bursitis, 
MR verified labrum tears and X-ray verified pathology of any 
kind did not predict poor or good clinical outcomes.
The identification of data acquired at baseline or at three 
weeks post induction into the study for association with out-
comes at 3 and 6 months, will inform the secondary analysis 
for potential predictive models and will be reported on in Part 
2 of this report. consistent with previous research on other 
painful musculoskeletal disorders, we have found that a poor 
outcome was associated with lower self-reported general health 
scores, and fear avoidance as it relates to work activities. In 
contrast, the instruments we employed for measuring other 
psychosocial factors were not strongly associated with 3- or 
12-month outcomes.
Limitations
the current study was not a randomized controlled trial and 
cause/effect relationships are outside the scope of the design. 
treatment methods by GPs and physiotherapists after the 
3-week assessment were not standardized or controlled, so 
causal relationships between different oral medications or 
physiotherapy interventions and outcomes cannot be estab-
table III. Number of cases reporting recurrences and re-injuries during intervals between follow-up assessments
Interval between 3-week 
and 3-month follow-up
Interval between 3-month 
and 6-month follow-up
Interval between 6-month 
and 12-month follow-up
total incidents/
events
Recurrence no re-injury 10 12 19 41
Recurrence with re-injury 8 2 9 19
Re-injury without recurrence 1 7 4 12
no recurrence or re-injury 122 115 103 n/A
totals 141 136 135 72
n/A: not applicable.
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lished. nevertheless, the current design allowed us to evalu-
ate outcomes associated with current practice in a pragmatic 
fashion. this would not have been possible with a more rigid 
design that did not allow clinicians the option to make appro-
priate treatment choices based upon the individual patient. In 
general the main treatment choices reflected nationally based 
guidelines.
Conclusion
Patients managed in a manner broadly consistent with guide-
lines for shoulder pain in primary care, demonstrate improve-
ment in pain and disability over a 12-month period. however, 
a moderate proportion still reported pain and disability at 12 
months and many reported recurrence of pain during this pe-
riod. While 30% show dramatic improvement with a structured 
corticosteroid injection protocol at the 3-week follow-up, 
mean pain and disability stayed rather static over the next few 
months, but improved in the 6–12-month period, regardless of 
symptom duration at presentation. there is evidence to sup-
port the hypotheses that a corticosteroid injection is a valuable 
treatment modality for selected patients in the short term. the 
prolonged course of recovery for many with shoulder pain 
requires further investigation to determine whether improve-
ments in diagnostic and/or treatment processes may reduce 
recovery time, reduce costs and result in more rapid return of 
shoulder function. Part two of this report will present results 
of multivariate predictive modelling for clinical outcomes.
The authors declare no conflicts of interest.
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APPENDIX I. Association of variables to clinical outcome at 3 and 12 months
Excellent outcome better Poor outcome
3 months
oR (p-value)
12 months
oR (p-value)
3 months
oR (p-value)
12 months
oR (p-value)
3 months
oR (p-value)
12 months
oR (p-value)
Variables derived from Part-1 analysis
SPAdI total Score (%) at baseline 1.018 (0.032) 1.000 (0.990) 0.988 (0.124) 0.997 (0.687) 0.983 (0.294) 1.032 (0.210)
SPAdI Pain Score (%) at baseline 1.016 (0.055) 0.995 (0.548) 0.990 (0.192) 1.003 (0.705) 0.984 (0.289) 1.020 (0.458)
SPAdI disability Score (%) at baseline 0.994 (0.460) 0.995 (0.530) 1.010 (0.230) 1.006 (0.465) 0.984 (0.343) 0.990 (0.737)
history of Asthma 0.573 (0.238) 0.438 (0.075) 1.379 (0.455) 2.068 (0.112) 1.702 (0.454) 2.326 (0.498)
Past history shoulder pain in the same shoulder 0.825 (0.605) 0.637 (0.236) 1.257 (0.521) 1.163 (0.693) 0.825 (0.784) n/A
Pain aggravated when reaching across the body 0.520 (0.058) 0.705 (0.326) 1.479 (0.237) 1.197 (0.615) 2.316 (0.229) n/A
Pain is eased or at best when at rest 0.553 (0.154) 0.350 (0.014) 1.467 (0.329) 2.919 (0.012) 1.733 (0.467) 0.880 (0.929)
Pain described as constant (24/7) 2.057 (0.054) 1.291 (0.510) 0.569 (0.124) 0.756 (0.474) 0.604 (0.531) 1.257 (0.854)
Sf-8_bodily Pain Score at baseline 0.991 (0.656) 0.998 (0.940) 0.990 (0.617) 0.995 (0.811) 1.070 (0.080) 1.079 (0.302)
Sf-8_General health Score at baseline 1.048 (0.067) 1.032 (0.215) 0.954 (0.056) 0.986 (0.584) 1.014 (0.763) 0.836 (0.040)
Sf-8_Physical functioning Score at baseline 0.973 (0.176) 0.993 (0.744) 1.007 (0.737) 1.007 (0.752) 1.106 (0.077) 1.003 (0.967)
Sf-8_Role Physical Score at baseline 1.003 (0.903) 1.013 (0.544) 1.005 (0.813) 0.995 (0.813) 0.976 (0.498) 0.923 (0.232)
Sf-8_vitality at baseline 1.035 (0.183) 0.996 (0.886) 0.964 (0.137) 1.018 (0.501) 1.019 (0.693) 0.883 (0.105)
Sf-8_Physical component Score at baseline 1.028 (0.186) 1.021 (0.284) 0.980 (0.308) 0.988 (0.537) 0.984 (0.624) 0.934 (0.133)
baseline vAS (mm) lowest level of pain 0.985 (0.263) 0.978 (0.092) 1.009 (0.464) 1.026 (0.053) 1.013 (0.505) 0.006 (0.992)
baseline vAS (mm) highest level of pain 0.985 (0.045) 0.991 (0.230) 1.013 (0.060) 1.009 (0.264) 1.001 (0.924) 1.008 (0.758)
fAbQ Work Score (%) at baseline 1.001 (0.926) 0.993 (0.405) 0.990 (0.188) 1.002 (0.823) 1.032 (0.027) 1.059 (0.081)
baseline fAbQ total (%) 1.000 (0.977) 0.997 (0.731) 0.990 (0.258) 0.995 (0.641) 1.038 (0.034) 1.116 (0.035)
frozen shoulder: clinical diagnosis 0.980 (0.978) 3.182 (0.159) 1.402 (0.642) 0.346 (0.196) n/A n/A
Pain intensity of index test pain at 3 weeks 0.982 (0.003) 0.987 (0.024) 1.009 (0.085) 1.017 (0.005) 1.022 (0.041) 0.895 (0.290)
Variables suggested by previous studies
Sf-8 Mental component Score at baseline 0.973 (0.174) 0.993 (0.727) 1.024 (0.225) 1.007 (0.737) 1.007 (0.851) 1.003 (0.960)
fAbQ General Score (%) at baseline 1.011 (0.270) 1.015 (0.175) 0.986 (0.140) 0.982 (0.124) 1.014 (0.418) 1.020 (0.542)
duration of symptoms (pain onset to initial clinical 
examination in days) 0.998 (0.207) 1.000 (0.913) 1.000 (0.791) 1.000 (0.915) 1.002 (0.088) 0.969 (0.267)
Gender is female 1.329 (0.401) 0.615 (0.165) 0.745 (0.367) 1.565 (0.203) 1.121 (0.856) 1.667 (0.680)
concurrent cervical spine symptoms 0.727 (0.435) 0.868 (0.724) 1.230 (0.592) 1.008 (0.985) 1.314 (0.696) 3.282 (0.338)
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APPENDIX I. contd.
Excellent outcome better Poor outcome
3 months
oR (p-value)
12 months
oR (p-value)
3 months
oR (p-value)
12 months
oR (p-value)
3 months
oR (p-value)
12 months
oR (p-value)
history of pain in the opposite shoulder 1.090 (0.814) 1.767 (0.126) 1.116 (0.753) 0.564 (0.125) 0.523 (0.305) 0.989 (0.993)
Pain is referred below the elbow 0.695 (0.448) 2.203 (0.109) 1.479 (0.237) 0.508 (0.168) 1.093 (0.913) 0.000 (0.998)
Shoulder pain disturbs sleep 0.620 (0.167) 0.576 (0.128) 1.283 (0.454) 1.700 (0.146) 2.127 (0.280) 1.368 (0.800)
Waist circumference (cm) 0.983 (0.178) 0.985 (0.196) 1.014 (0.237) 1.018 (0.146) 1.005 (0.828) 0.975 (0.599)
Pain is aggravated by reaching above the head 1.162 (0.733) 0.674 (0.385) 1.036 (0.934) 1.665 (0.262) 0.442 (0.446) n/A
Shoulder pain provoked by neck movement testing 0.995 (0.977) 0.876 (0.458) 0.893 (0.494) 1.109 (0.563) 1.440 (0.181) 1.323 (0.581)
Variables derived from imaging studies
PAR to diagnostic injection to the SAB (≥ 80%) 0.768 (0.462) 0.800 (0.531) 1.451 (0.279) 0.991 (0.981) 0.607 (0.474) n/A
Positive anaesthetic response to diagnostic injection to 
the ACJ joint (≥ 80%) 1.390 (0.525) 0.219 (0.026) 1.102 (0.850) 3.372 (0.052) n/A 3.808 (0.020)
PAR to diagnostic injection to the GHJ joint (≥ 80%) 5.444 (0.009) 0.556 (0.352) 0.366 (0.085) 1.800 (0.352) 0.400 (0.405) n/A
Thickening, fluid or calcification of the SAB on 
ultrasound imaging 0.307 (0.005) 1.029 (0.939) 2.662 (0.009) 0.969 (0.932) 1.216 (0.764) 1.035 (0.978)
AcJ arthropathy of any sort seen on x-ray 0.653 (0.402) 0.662 (0.398) 1.692 (0.279) 1.681 (0.287) 0.564 (0.593) n/A
AcJ arthropathy of any sort seen on MRI 0.765 (0.618) 0.437 (0.105) 0.773 (0.594) 2.291 (0.105) 3.208 (0.164) n/A
Subacromial ‘bursitis’ seen on MRI 0.809 (0.728) 0.778 (0.665) 1.197 (0.744) 1.286 (0.665) 0.981 (0.982) n/A
labrum tear seen on MRI 1.528 (0.433) 0.941 (0.903) 0.607 (0.298) 1.062 (0.903) 1.445 (0.605) n/A
frozen shoulder: clinical diagnosis 0.980 (0.978) 3.182 (0.159) 1.402 (0.642) 0.346 (0.196) n/A n/A
Moderate or major rotator cuff tears as identified on 
ultrasound imaging 0.390 (0.154) 0.967 (0.951) 1.281 (0.644) 1.144 (0.806) 3.562 (0.083) n/A
GhJ synovitis (generalized or local) seen on MRI 1.308 (0.618) 0.384 (0.065) 1.293 (0.594) 2.607 (0.065) 0.312 (0.164) n/A
diagnostic anaesthetic injection only provided to a subset of patients referred for MR arthrogram i.e. those who reported less than 80% pain reduction 
following diagnostic blocks to the subacromial bursa and the acromioclavicular joint.
Classification of cases as having a “frozen shoulder” was derived from the physical examination findings at baseline and based on 50% or more 
reduction in passive range of motion (compared with other side) in two or more of the following planes: abduction, external rotation, internal rotation.
N/A: insufficient data and/or no variation in the variable (e.g. all values the same for a particular variable); SPADI: Shoulder Pain and Disability Index 
Questionnaire; SF-8: Short Form 8 questionnaire; FABQ: Fear Avoidance Beliefs Questionnaire; VAS:visual analog scale; GHJ: glenohumeral joint; 
SAb: subacromial bursa; AcJ: acromioclavicular joint; MRI: magnetic resonance imaging.
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